Ion Exchange (India) Ltd. (IEIL)

SEBI Research Analyst Registration No: INH000009843
Ion Exchange (India) Ltd. (IEIL)
Initiating Coverage
03rd November, 2022
CMP: 2066.7| Target Price: 2610

Upside Potential: 26% | Duration: 1 Year
Market Capitalisation: ₹3031 Cr
Market Capitalisation : ₹732 Cr

Research Analyst – Tushar Raghatate, Ajinkya Jadhav, Mohit Chandnani
Investors are advised to refer through important disclosures made at the end of the
Research Report.
tttt
Index
ABOUT .................................................................................................................................................................................. 3
CORPORATE GOVERNANCE ........................................................................................................................................ 6
INDUSTRY ANALYSIS ...................................................................................................................................................... 7
THE COMPANY ................................................................................................................................................................ 13
TRIGGERS .......................................................................................................................................................................... 23
SHAREHOLDING PATTERN (Q2FY23)...................................................................................................................... 28
PEER DESCRIPTION ...................................................................................................................................................... 29
PRICE HISTORY AND PERFORMANCE ................................................................................................................... 30
FINANCIALS ...................................................................................................................................................................... 31
VALUATIONS .................................................................................................................................................................... 40
SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

ABOUT
Incorporated in 1964, Ion Exchange (India) Ltd. (IEIL) was founded by the Late G.S Ranganathan. He was
working in the UK-based Permutit Company and on his recommendation, Permutit Company incorporated
IEIL as its 60% subsidiary. The foreign holding was reduced in a phased manner and the paid-up share
capital has been held by resident Indians since 1995. The Company was the pioneer of resin manufacturing
in India in 1965 and currently holds a 40% market share of resin in India. IEIL diversified into the chemical
treatment of water in 1982.
The Company operates in three key segments Engineering, Chemical and Consumer products. The
Engineering business has 11-12% EBIT margin whereas the chemical business has 21-24%. EPC business is
driven by green field capex by the end user industry whereas the Chemical division is driven by opex. The
Company has a presence in entire water and waste water treatment value chain from preliminary
treatment to zero liquid discharge. Very few companies in India provide solutions across spectrum of water
and waste water management.
IEIL manufactures resins in Ankleshwar, Gujarat and water chemicals in Hyderabad, Telangana. They are
doubling the resin capacities through the green field capex at Roha, Maharashtra which will be operational
in FY24. The Company has in-house manufacturing of membrane at Verna, Goa which is used in different
technologies of water and waste water treatment. The Company is undergoing brownfield Capex of Rs. 49
Cr. which will be operational in Q4FY23. They have fabrication and assembly plants in Tamil Nadu,
Maharashtra in India and UAE, Bangladesh and Indonesia overseas.
The Company has seasonality in its business, with Q4 garnering the highest revenue and EBIT margin. The
overall scale of operations is much higher in the last quarter which helps the company to leverage the fixed
cost and supports them to scale EBIT margin. Further, the favorable product mix shift leads to a higher
profit margin in Q4. In comparison, Q1 is the smallest considering the contribution to revenue.

MILESTONES
1964 Incorporated as 60% subsidiary of Permutit, UK.
1965 Pioneered the production of world-class ion exchange resins in India.
1969 Awarded the 1st major contract from Chennai Petroleum Corporation Limited (CPCL).
1976 R&D was recognized by the Department of Science & Technology (DST), India.
1977 Listed on Bombay Stock Exchange, India.
1978 The 1st The Company in India to introduce the Reverse Osmosis concept.
1979 Ion Exchange resins manufacturing unit was inaugurated at Ankleshwar, India.
1982 New engineering & fabrication facility was set-up at Hosur, India.
1985 Ion Exchange becomes a wholly owned Indian Company after Permutit’s divestment.
1987 1st in India to manufacture Reverse Osmosis membrane elements at Halol Kalol, India.
1991 Established the international division and started Southeast Asia operations.
Bagged the order for the world’s largest Clarifier for a pulp & paper mill.
1994 Capacity expansion and complete automation of resins manufacturing unit at Ankleshwar,
India.
1997 100% Export Oriented Unit (EOU) set up at Rabale, India.
1998 Consumer product manufacturing starts at Goa, India under the brand name ZeroB.
2002 Launched Water Vending Stations.
2003 1st packaged drinking water plant was commissioned for Indian Railways ‘Rail Neer’.
2010 Largest Reverse Osmosis based Sea Water Desalination (SWD) plant in the industrial sector
was commissioned for Chennai Petroleum Corporation Limited (CPCL).
2017 India’s 1st integrated Reverse Osmosis membrane manufacturing facility was set up in Goa,
India.
2021 Awarded a large EPC project from State Water Supply and Sanitation Mission, Namami Gange
and Rural Water Supply Department under the Jal Jeevan Mission, Government of India.

PROMOTERS AND MANAGEMENT TEAM
● RAJESH SHARMA, MANAGING DIRECTOR
1. He has an experience of more than 4 decades in providing Total Water

Management solutions to all sectors. Mr. Sharma joined the Company
in 1974 and has held various positions in sales, marketing and
management. Before taking over the office of Managing Director in
April 2000, he was the Deputy Managing Director.
2. He established the company’s international business division, including

its 100% EOU and has developed business relationships with leading
engineering contracting companies and business & technology
partnerships with leading companies in Europe, Japan, South East Asia
and the Far East.
3. Mr. Sharma has chaired technical seminar sessions organized by

various Associations and also presented papers in India and abroad on
water and wastewater treatment and water conservation topics.
4. He holds 5.62% of total equity share and takes total remuneration of

Rs. 6.6 Cr. which is 4.2% of FY22 Net profits of Rs. 162 Cr. Commission
is ~23% of total remuneration.
● AANKUR PATNI, EXECUTIVE DIRECTOR
1. He is associated with the Company for the last 20 years. Mr. Patni is a
Chartered Accountant.
2. He is currently associated with 8 Companies and is a director with

Rockmen Merchants Ltd, Global Composites and Structurals Limited,
Ion Exchange Infrastructure Limited, Aquanomics Systems Limited,
Astha Technical Services Limited, Ion Exchange Projects and
Engineering Limited, Total Water Management Services (India) Limited.
3. He holds 2.01 % of Total equity shares and takes total remuneration of

Rs. 3.02 Cr (1.85% of FY22 Net profits). The commission is ~25% of total
remuneration. He is son of M.P Patni (Non-executive director) whose
age is 75 plus.

CORPORATE GOVERNANCE
Positive Negative
Checklist Remark
Auditors’ opinion Unmodified
Auditor change No Frequent change in Auditor
Promoter pledged % No history of promoter pledging since listing
Conference call Yes, shows investment friendliness
Investment presentation Yes, shows investment friendliness
Related party transaction (Loans given
No repayment schedule of loans given to subsidiaries
to subsidiaries)
Subsidiaries Complex subsidiaries structure in India and Offshores
Independent Directors as % of Board 50%, Good sign

INDUSTRY ANALYSIS
GLOBAL WATER AND WASTEWATER TREATMENT SOLUTIONS MARKET
• The value of the global water and wastewater treatment solutions market grew by 5.3% from
US$760 billion in CY2021 to US$801 billion in CY2022. It is expected to grow at a CAGR of 4.7%
from US$801 billion in CY2022 to reach US$1,057 billion in CY2027.
Global Water and Wastewater Treatment Solutions Market Size: Historical

and Forecast, CY 2019 – 2027, Source- Concord Enviro Systems Limited RHP
Water and Wastewater Treatment Solutions Market Forecast

by Region, 2019 – 2027, Source- Concord Enviro Systems Limited RHP

• The demand for water and wastewater treatment solutions in APAC is mainly driven by rapid
urbanization in developing Asian economies including China, India, Vietnam and Indonesia.
Growing manufacturing and services sectors are creating demand for recycling and reuse
systems.
• Other factors that are contributing to the growth of the market are improving standards of living,
water scarcity, and emergence of more stringent water related laws and regulations, particularly
for effluent discharge. River cleaning initiatives in India, China, Indonesia, and the Philippines
have led to strongest enforcement of regulatory compliance, and imposition of recycling and
reuse systems with the provision of subsidies or incentives for implementation.
INDIA’S WATER AND WASTEWATER TREATMENT SOLUTIONS MARKET
• Indian Wastewater treatment solutions segment is forecasted to grow at a CAGR of 8.8% from
Fiscal 2021 to Fiscal 2031 and Indian water & environment industry is projected to register a
healthy CAGR of 8.5 percent during the period 2022-2026.
India’s Water and Wastewater Treatment Solutions Market

Forecast, FY 2021 – FY2031, Source- Concord Enviro Systems Limited RHP

Indian water and wastewater treatment solutions market by segments, FY21,
Source- Concord Enviro Systems Limited RHP
• The industrial segment is expected to grow faster than the municipal segment during
the forecast period. Backed by investments and regulations, the industrial segment is
anticipated to grow at a CAGR of 11.7% from Fiscal 2021 to Fiscal 2031, The municipal
segment is expected to record a CAGR of 7.2% across the same period.
Total Water and Wastewater Treatment Solutions Market Forecast

by End User Segments, India, FY2021 – FY2031,

• Steel industry used to be a major contributor in the past, but its share in the market has
declined over the years owing to the lack of investment in the industry. Highest growth
expected as per end user industry is majorly in Pharmaceuticals - 17% CAGR, Food & Beverage
- 16.7% CAGR and Chemicals - 15.3% CAGR.
Industrial Wastewater Treatment Solutions Market Forecast

by End-user Segment, India, FY 2021–FY2031, Source- Concord Enviro Systems Limited RHP
• Refineries have been the largest end-user segment for the industrial wastewater treatment
market In India, propelled by capacity addition, Bharat Stage (BS VI) conversion projects and
larger ticket sizes. Chemicals, power, textile, pharmaceuticals, food and beverage fertilizer and
distillery companies are the other major end-users.

Indian industrial wastewater treatment solutions market by
end-user segments, FY21, Source- Concord Enviro Systems Limited RHP
• India is lagging in terms of Sewage treatment capacity. Total sewage generation is 72,368 MLD,
of which India has the capacity to treat 44% of the sewage while only 28% of sewage is treated.
There is huge head room to grow for the sewage treatment companies as industrialization
increases and the Government focuses on reducing open sewage disposal.
Sewage Generation and Treatment Capacity, Urban India, 2020,


• The technologies employed by the industrial wastewater treatment solutions market are further set out
below:

THE COMPANY
• The Company has presence in the entire value chain from preliminary treatment to zero liquid
discharge. Very few companies in India provide solutions across the spectrum of water and
waste water management.
• The Company has in-house manufacturing of membranes which is used in different

technologies for secondary and tertiary treatment.

BUSINESS SEGMENT
FY22 Sales
34.00%
58%
8.00%
Engineering Chemical Consumer products
1. ENGINEERING (58% OF FY22 SALES, 10-12% EBIT MARGIN)
Global Market size of Engineering Segment is Rs. 4.5 Lakh Cr. While in India it is Rs. 40,000
Cr and in Industrial segment it is Rs. 8,000 to 10,000 Cr. Of the total Engineering segment
sales, IEIL derives ~10% of revenue from membranes, ~15–20% from O&M services, and
the rest from remaining EPC related contracts.
a) INDUSTRIAL SEGMENT
I. Ion Exchange integrates process technologies and design, engineering & project
management expertise into design & build projects – on turnkey, BOOT or EPC
basis.
II. The Company provides customized solutions for water, waste water, recycle, ZLD to
core industries such as power plants, chemicals, refineries, fertilizer and steel
plants. It provides comprehensive turnkey solutions for Municipal Water, Waste
Water and Solid Waste Management.
III. Normal execution period of contracts is 2 years. (Mix of large and small). Mid-sized
contracts take 1-1.5 years for execution whereas for small contracts it takes 3-6
months for execution. Company has 40% private contracts in its current order book.

IV. Standard systems
i. Packaged and pre-engineered range – The Company provides solutions for

softeners, filters, demineralizers, membrane plants, packaged sewage and
industrial effluent treatment plants. Engineered to meet the necessary
process water, non–water and treated waste water quality requirements of
diverse industries like pharma, food and beverages, automobile, textile etc.
ii. These pre-engineered, pre-tested and skid-mounted fast delivery systems
are also the preferred choice for industries like hospitality, realty, IT parks,
malls etc.
b) COMPREHENSIVE SERVICES- O&M CONTRACTS
I. Annual Maintenance - They provide Water & Waste Water equipment for
efficient performance and zero downtime, scheduled inspection visits and
scheduled maintenance & services.
II. Comprehensive service contract- IEIL takes complete responsibility for supply
of treated water in required quantity and quality at the customer’s place. The
Company also provides solutions for Boiler & Cooling Water Treatment
Programs and Consultancy & Surveys.
c) MEMBRANES
Sea Water RO Membrane Low Pressure RO Membranes Brackish Resistant Membranes

Fouling Resistant Membranes Nano Filtration Membrane Ultra Filtration Membrane
a) In 1987, Ion Exchange pioneered and promoted the concept of reverse osmosis
membranes in India and started manufacturing membranes. The Company’s
manufacturing facility in Goa manufactures a wide range of Reverse Osmosis and
Nano Filtration membranes.
b) Ion Exchange offers its Membrane under the brand HYDRAMEM - High
performance membranes. Currently, 20–25% of production is captively
consumed, while external sales contribute ~10% to revenue.
c) Industrial, institutional and domestic applications of membranes are as follows:
i. Conventional Industrial Water Treatment – Brackish water Hydramem

membranes are used for purification of process water. Hydramem
membranes give best in class salt rejection recoveries with optimum
permeate water flow.
ii. Sea Water Desalination – With their increased efficiency and lower power
requirements Hydramem Sea Water elements offer desalinated water at
lower costs.
iii. Recycling of Treated Effluents – Hydramem Fouling Resistance
Membranes provide superior organic fouling resistance, longer life and
less frequent cleaning.
iv. Textile Industry – INDION Salt Recovery system from Textile dye bath
effluent based on specialty NF membrane technology recovers brine for
its reuse in dyeing process & recovers water to be recycled in various plant
processes.
v. Dye Desalting – Hydramem NF membranes efficiently removes
undesirable impurities from variety of dyes and enhances their functional
properties.

2. CHEMICAL (34% OF FY22 SALES, >20% EBIT MARGIN, >50% OF FY22 PAT)
• Water treatment chemicals are used for raw and waste water treatment conditioners in
boiler, cooling water treatment and membrane cleaning etc. Industry Chemicals are used to
increase the life of boilers and to reduce maintenance costs, corrosion, scaling chemicals, PH
conditioning. The Company is engaged in the manufacturing of water treatment chemicals
such as ion exchange resins and other specialty chemicals.
• Specialty Chemicals include performance chemicals used in the processing of Paper, Sugar,
Ceramic, Pharma and Refinery products. The Company also has a FDA approved pharma
grade resin facility.
• IEIL offers products under the registered trademark of INDION RESINS which include
complete range of cation and anion resins for water and waste water treatment, purification
of bio-diesel, sugar, food and beverages & host of specialty applications like pharmaceutical
excipients, catalysts, nuclear grade resins, brine softening, heavy metal removal, adsorbent
grade resins etc.
• India’s Resin market size is Rs. 300 Cr. The Company has 40% market share of Resin in India.
Resins are being imported in India and Thermax Ltd. is the major competitor.
• The Company exports to USA, Canada, Middle East, Japan, Korea and has a low single digit
global market share. Du Pont USA (2021 Revenue of USD 15.13 Billion) and LANXESS
European company (2021 Revenue of EUR 6.1 billion) are the major producers of resin and
cover almost 60% of global market share.
• R&D is an ongoing process and the Company has vast experience of working with many
companies to make tailor made solutions (Value added product) and come up with new
solutions for customers which improves client stickiness.
• Application
In industries, raw water enters in the plant which needs treatment to achieve right
specifications. Additionally, the used water which is thrown out needs specifications for
disposal. A one-solution-fits-all framework does not work every single time when there is a
large scale implementation. Resins are used for removal of colour, odour, organics, nitrate,
iron, fluoride, arsenic and tannin. Electronics manufacturing requires ultra-pure water
because even the slightest impurities can cause malfunction, which is similar to medical and

pharma industries. Tailor-made resins are developed to suit specific applications. The process
flow is shown below.
a) Study input raw water quality.

b) Quality required by the customer.
c) Treatment criteria.
d) Discharge norms.
3. CONSUMER PRODUCTS (8% OF FY22 SALES, NEGATIVE EBIT MARGIN IN FY22)
• Ion Exchange is the pioneer of the RO technology, in India. With its National & International
presence, the Company offers its products in Consumer products business under the brand
Zero B.
• Besides Zero B products which cater to individuals, hotels, spas, educational institutions,
hospitals, laboratories, railway and defence establishments, this division also provides several
technologically advanced products to residential, commercial and rural segments.
• IEIL has focused on niche products (having a unit price of up to Rs. 3 lakh vs generic RO price
of Rs. 15,000–20,000/piece) that provide hydrogen and mineral-rich water. The Indian water
purifiers market was worth USD 754.2 million in 2020 and is further projected to reach USD
1937.5 million by the year 2027, growing at the CAGR of 14.3% during the forecast period (2020-
2027).
• This business was loss making at EBIT level and IEIL witnessed turnaround in this segment in
Q1FY23.

RAW MATERIAL
• Steel and cement are the major raw material used in Engineering business whereas in
Chemical business it is petrochemicals. Chemical division raw materials are majorly imported.
MARQUEE CLIENTS
• Industrial – NTPC, NPC, Reliance, IOCL, JSW, CPCL, L&T, ArcelorMittal, Nippon Steel, Nayara Energy,
IRCTC, BHEL, Tata Group.
• Institutional – Leela, Military Engineering Services, Taj Hotels, Holiday Inn, Hyatt Regency, Oberoi
Hotels, Apollo Hospitals, Escorts Heart Institute, DLF, Puravankara.
• International – Cargill, Technip France, Unilever Group, Jurong, Thyssenkrupp (Uhde), Jacobs,
Kawasaki, Mitsubishi, PDO Oman, Emirates Steel, IKPP Indonesia.

MANUFACTURING FACILITIES
Location Type of unit

Ankleshwar, Gujarat (India) Resins Manufacturing Unit
Hyderabad, Telangana (India) Industrial Chemicals Manufacturing Unit
Membrane Manufacturing Unit, Fabrication
Verna, Goa (India)
& Assembly Unit
Hosur, Tamil Nadu (India) Fabrication & Assembly Unit
Rabale, Maharashtra (India) Export Oriented Unit
Wada, Maharashtra (India) Fabrication Unit
Sharjah, UAE Assembly Unit
Indonesia Assembly Unit
Dhaka, Bangladesh Fabrication & Assembly Unit
• Ion operates 9 manufacturing units, including a fabrication unit in the UAE, Indonesia, Bahrain
and Bangladesh

INTERNATIONAL PRESENCE AND EXPORTS
● The Company markets its products through 600+ dealers in FY22. (300+ in FY18)
● Exports contributes 30% to the total revenues.
SUBSIDIARIES
• Ion Exchange (India) Limited has 18 subsidiary companies in India and abroad as on March 2022.
Ion Exchange LLC, USA, Ion Exchange Asia Pacific Pte. Ltd., Singapore, Ion Exchange Projects and
Engineering Ltd. India (91% owned) are the major subsidiaries which are 100% owned.
STRENGTHS
● The Company has a chemical resin and membrane facility which is utilized captively. The Company
has long term relationships with major clients and has been providing solutions to them for tailor-
made products which improve client stickiness.
● The Company has a 40% market share in the resin market in India itself. The Company expects to
increase its global market share which is in the low single digits.

● It has two facilities for in-house R&D and two applications and testing centers. The company has
over 50 patents to its credit and 100+ products commercialized.
● The company has a global presence apart from presence in major cities in India with 36+ sales &
service centers and 100+ Channel Partners.

TRIGGERS
ONGOING UP PROJECT AND UPCOMING EPC PROJECTS TO START CONTRIBUTING TO THE

TOPLINE
• The Company had got major contract of Rs. 1000 Cr. in Uttar Pradesh Q4FY21 under the Jal Jeevan
Mission for the rural water drinking supply to 1,000 villages in two districts of Uttar Pradesh that is
Varanasi and Aligarh. Under this contract, the Company is involved in extracting and treating
groundwater, and supplying drinking water to households.
• Every village has its own different contract hence it’s a major contract with a compilation of various
small contracts. The scope of work might increase in the contract going forward as there are various
moving parts in the contract. The contract order is in a staggered manner and the current value of
this contract stands at Rs. 1200 Cr.
• Outstanding contract order which is yet to be executed is valued at Rs. 1135 Cr. Of this amount, we
expect Rs. 350 Cr to be realized in FY23 and major chunk of more than Rs. 800 Cr. in FY24. This
contract has a timeline of 18-21 months. The Company will be getting recurring O&M business of
10 yrs. from this contract. (O&M stands for Operation and Maintenance)
• Depending on the attractiveness of the projects, IEIL may bid for more states for similar services.
ROBUST ORDER BOOK IN EPC AND STRONG BID PIPELINE OFFERS REVENUE VISIBILITY
• The Company has a total order book of Rs. 2,912 Cr. (Rs. 600 Cr. in Dec 2020, 4.8x growth) of which
outstanding UP SWSM is Rs. 1,138 Cr. (~40% of total order book) and the outstanding Sri Lanka
order is of Rs. 245 Cr.
• IEIL has a bid pipe line of Rs. 8,000 Cr. (majorly international) of which, as per management 30% of
their bid is at advanced stage which translates to Rs. 2,400 Cr. If the conversion happens the total
order book will be Rs. 5,312 Cr. (3.37x of FY22 revenue of Rs. 1,577 Cr.)
• Currently, O&M services contribute ~15–20% to revenue from the Engineering business. As the
order book grows, scope for O&M services will also improve.
• IEIL had frontloaded the cost for strengthening the infrastructure on the back of increased order
backlog and expects increased pace of execution in the coming quarters.

UPCOMING GREEN FIELD CAPEX IN RESINS (CHEMICAL DIVISION) AND BROWN FIELD CAPEX
IN MEMBRANE BUSINESS
• The Chemical business contributes 34% to the revenue and has 22-24% EBIT and contributes 50%
to the total profits of the entire business. The current capacity for Resins- 36,000 TPA, is running at
70-75% utilization levels. The facility is expected to get optimally utilized at 90% by FY24.
• The Company is doing a green field Capex of >Rs. 250 Cr. in Roha, Maharashtra to enhance resin
capacity. The Capex will have 2 phases. Phase 1 (P1) will double the existing capacity of 36,000 TPA
in Cation and Anion Resin each and in Phase 2 (P2) further 36,000 TPA will be added to each resins.
The existing capacity will be 3x of current capacity, post the P2 expansion.
● This Capex can achieve 2.5-3x of asset turnover which translates to Rs. 625-750 Cr. in revenue (40-
48% of FY22 sales) at full utilization. The Company expects to increase its global market share which
is in low single digits and the Company is expecting the expanded capacity to be fully utilized within
2-3 years.
• IEIL is undergoing brownfield Capex of Rs. 49 Cr. in the Membrane business which runs at 90%
utilization level. The expanded capacities will be live by Q4FY23. Expected revenue from this Capex
would be Rs. 60-70 Cr. (4- 4.4% of FY22 sales) at full utilization.
HUGE GROWTH IN CONSUMER DIVISION ALONGWITH PROFITABILITY
• IEIL witnessed turnaround in the Consumer business. As per our conservative estimates we expect
this division to grow by 30% CAGR till FY24 from a low base of Rs. 157 Cr. (FY22) which translates
to Rs. 265 Cr. by FY24 (Management has guided for upwards of 50% CAGR growth for FY23)
• IEIL has focused on niche products (with a unit price of up to Rs. 3 lakh vs generic RO price of Rs.
15,000–20,000/piece) that provide hydrogen and mineral-rich water. This segment became
profitable at the EBIT level in Q1FY23 and is likely to see improvement in the future.
STRONG REVENUE VISIBLITY WITH MARGIN IMPROVEMENT IN CHEMICAL BUSINESS
• We expect the topline will grow by 20% CAGR till FY24 (the management has guided 40% growth for
FY23 YoY). The EBIT margins will be in the range of 13-14%.
• As per our conservative estimates we expect EPC to grow by a CAGR of 21% till FY24 which translates
to Rs. 1347 Cr. by FY24 and the Chemical business to grow by 13% CAGR till FY24 which translates
to Rs. 712 Cr. by FY24 (FY22 Rs. 558 Cr.) whereas Consumer division will grow by 30% on a low base
which translates to Rs. 265 Cr. by FY24 Cr.

(All figures are in Rs. Cr. unless mentioned otherwise)
2 YR CAGR
FY20 FY21 FY22 FY23E FY24E
growth
Total REVENUE 1480 1450 1576 2049 2295 21%
EPC 939 941 935 1218.9 1346.47 20%
Growth in % 0% -1% 30% 10%
CHEMICAL 469 440 558 652 717 13%
Growth in % -6% 27% 17% 10%
CONSUMER 126 108 137 178.1 231.53 30%
Growth in % -14% 27% 30% 30%
CASH RICH BALANCE SHEET WITH NEGLIGIBLE DEBT CUSHION FOR UPCOMING Capex
• The Company stands at a cash surplus of Rs. 536 Cr. (March 22), which includes Rs. 43 Cr. margin
money related to specific EPC contracts in an escrow account and Rs. 197 Cr. margin money
deposited with banks.
• The Company possesses unblocked cash of Rs. 296 Cr, which is sufficient enough for Phase 1 green
field Capex in the Chemical division.
CONSOLIDATION OF ALL SUBSIDIARIES TO REDUCE RELATED PARTY TRANSACTIONS
• The Company will be consolidating all its subsidiaries in H2FY23. This will help The Company to form
a simple structure and evade the complex related party transaction.
TAILWINDS TO THE WATER AND WASTE WATER TREATMENT INDUSTRY
• Capital expenditure on water and waste water infrastructure in India is set to increase by 83% over
the next five years, hitting an annual run rate of USD 16 Bn by 2023. In 2001, per capita water
availability was 1,820 cubic meters which is projected to decline to 1,140 cubic meters by 2050.
• Almost 62,000 MLD of sewage is generated across urban India and there are just 816 STPs installed
that treat 23,277 MLD or 37.5% of sewage per day. The Govt. of India plans to spend Rs. 200 bn in
the next 5 years for the Clean Ganga project.
• Global water treatment chemical market size is expected to grow from $39.1 billion in 2021 to $61.1
billion in 2026.

• Current coverage of Nal Se Jal is 8.7 Cr. households, of this 5.5 Cr. households were provided tap
water in the last 2 years itself. Allocation of Rs. 60,000 Cr. has been made with an aim to cover 3.8
crore households in 2022-23. All these factors provide strong push for the industry in which IEIL
operates.

Risks
• The Company received an order from Sri Lankan Government Authority, National Water Supply and
Drainage Board (NWSDB) in 2016. Out of this total contract, Rs. 250 Cr. is the outstanding contract
which is at a standstill due to economic crisis and political unrest. However, the management is
confident of completing the project with no credit risk as the payment is routed through Exim Bank.
• Competition risk from L&T water, Concord Enviro- (FY21 Revenue Rs. 348 Cr, IPO awaited main
board), Triveni engineering (Order book of Rs. 1,889 Cr, Technology till ZLD), Praj industries. The
company operates in the EPC industry which is fragmented.
• The steel and cement price movements would certainly have an impact on the Engineering
business. Similarly, the petrochemical prices (Crude derivative are a major RM cost) and other
commodity price movements on the chemical front would have an impact on the chemical segment.
The container unavailability due to any foreseen event can erode revenue and margins. The
Company is vulnerable to exchange rate fluctuations.
• Passing on the cost increase does not happen immediately and tends to have lag which could erode
the margins for the shorter run.

SHAREHOLDING PATTERN (Q2FY23)
1. Promoters- 27.01%
• No history of promoter pledging shares.
2. Others- 16.18%
• Multiple trusts created by promoters and employees.
3. FII- 0.71%
4. DII-10.82%
5. Public- 45.28%

PEER DESCRIPTION
• The major industrial wastewater recycling and reuse EPC companies are Ion Exchange, Concord
Enviro, Arvind Envirsol, Thermax and Suez. In FY2021, these five companies have a combined share
of 56.9%.
Competitive analysis of Indian industrial wastewater

treatment solutions market, 2021, Source- Concord Enviro Systems Limited RHP
Industrial wastewater recycles and reuse

solutions market in India,2021, Source- Concord Enviro Systems Limited RHP
• Zero liquid discharge is niche market where there are very few players of which Ion Exchange is
the major player with ~20% market share.

Va Tech Wabag Ltd
• Va Tech Wabag Ltd (VTWL) is Indian multinational player in the water treatment industry which
provides a turnkey solution for water and waste water treatment. WABAG’s offerings span across
municipal drinking water, municipal sewage, industrial water, industrial effluents, desalination and
recycling. The Company operates through EPC, O & M, DBO, BOOT, HAM models.
• VTWL has a total order book of Rs. 10,592 Cr. of which 52% is from India and 48% is from rest of the
world (Row). The order book comprises of 69% municipal and 31% Industrial segment contracts.
The said order book has 67% of EPC contracts and 33% of O&M contracts.
• Their 54% of revenue comes from India and 46% from the RoW. The projects have an average
execution cycle of 30-36 months, VTWL expects a 10% YOY sustainable growth in topline.
• VTWL had a 2-3% sales growth for last 3 yrs. with 7-8% EBIT margins with ROCE of 13-14%. Though
the company has a robust order book, 69% of its orderbook is from Municipalities which adds a
concentration risk for their order book. Working capital of VTWL has been stretched historically.
• Ion Exchange had a 10-11% sales growth for last 3 years with EBIT of 13-14% driven by Chemical
business majorly with EBIT margin of 22-24%. Company has a ROCE profile of 35-38%. IEIL
Judiciously selects contracts considering the credit profile of the issuer. Private orders comprise 40%
of the total order book.
• In our point of view, Ion exchange is well place as compared to VA tech Wabag in the water and
waste treatment space.
PRICE HISTORY AND PERFORMANCE
IEIL vs Nifty Small Cap 250

700
600
500
400
300
200
100
0
01-Apr-2019 01-Apr-2020 01-Apr-2021 01-Apr-2022
IEIL Nifty Small Cap 250

FINANCIALS
• PROFIT AND LOSS STATEMENT
(All figures are in crores unless mentioned otherwise)
Income Statement FY18 FY19 FY20 FY21 FY22 Growth

Revenue 1045.81 1162.28 1479.83 1449.52 1,576.87 10.8%
COGS 675.59 727.52 965.33 891.9 945.74 8.8%
Gross Profit 370.22 434.76 514.50 557.62 631.13 14.3%
GPM 35.4% 37.4% 34.8% 38.5% 40.0%
Other Manufacturing
179.44 199.04 237.17 229.82 274.2 11.2%
Expenses
Operating Expenses 110.73 126.84 139.48 123.39 141.81 6.4%
EBITDA 80.05 108.88 137.85 204.41 215.12 28.0%
EBITDAM 7.7% 9.4% 9.3% 14.1% 13.6%
DA 13.08 19.59 23.53 27.67 28.04

EBIT 66.97 89.29 114.32 176.74 187.08 29.3%
EBITM 6.4% 7.7% 7.7% 12.2% 11.9%
Other Income 21.09 33.34 35.37 33.09 42.5

Interest 21.74 21.35 19.25 14.72 12.67
EBT 66.32 101.28 130.44 195.11 216.91 34.5%
EBTM 6.3% 8.7% 8.8% 13.5% 13.8%
Taxes 26.36 35.94 36.73 51.71 55.64

39.7% 35.5% 28.2% 26.5% 25.7%
PAT 39.96 65.34 93.71 143.40 161.27 41.7%

NPM 3.8% 5.6% 6.3% 9.9% 10.2%

• BALANCE SHEET
Balance Sheet FY18 FY19 FY20 FY21 FY22

Assets
Non-current assets
Property, plant and equipment 143.58 150.66 145.89 148.64 144.60
Right-of-use assets 37.83 30.30 36.95
Capital work-in-progress 6.58 12.28 11.51 14.60 20.04
Goodwill 8.631 8.631 8.63 8.63

Other Intangible assets 1.28 1.38 1.59 2.16 1.93
Investment accounted using equity
method 2.98 3.44 3.75 3.56 3.98
Intangible assets under development
Financial assets
(i) Investments 0.70 0.70 0.7118 0.71 4.37
(ii) Trade receivables 13.79 14.20 6.25 4.54 4.54
(iii) Loans 9.93 9.99 11.77
(iv) Other financial assets 7.54 7.03 6.49 17.68 17.07
Deferred tax assets (net) 1.15 1.05 1.48 5.35 9.34
Non-current tax assets (net) 0.42 0.47 0.50 0.61 1.41
Other non-current assets 15.25 16.69 16.48 13.55 25.70
Total non-current assets 203.20 226.53 252.88 250.33 278.54
Current assets
Inventories 101.19 129.76 134.50 127.59 180.96
Financial assets
(i) Investments 0.40 0.37 0.11 0.24 0.32
(ii) Trade receivables 437.10 424.17 501.87 448.96 507.70
(iii) Cash and cash equivalents 67.25 45.17 101.46 197.23 169.08
(iv) Bank balances other than (iii) above 195.93 245.24 271.63 308.15 366.82
(v) Loans 16.88 9.08 17.32 14.24 20.12
(vi) Other financial assets 8.76 19.65 23.72 11.71 13.73
Current tax assets (net) 0.80 1.36 1.46 0.67 0.31
Other current assets 33.72 63.91 77.23 84.18 87.84
Total current assets 862.03 938.72 1,129.30 1,192.98 1,346.88
Assets held for sale

Total assets 1,065.22 1,165.25 1,382.19 1,443.31 1,625.41
Equity and liabilities
Equity

Equity share capital 14.23 14.23 14.23 14.23 14.23
Other equity 185.88 245.80 348.83 491.61 641.43
Total equity 200.11 260.03 363.05 505.84 655.66
Non- Controlling Interest 2.84 2.19 2.03 -0.12 -0.83
Total 202.94 262.21 365.08 505.71 654.83
Liabilities
Non-current liabilities
Financial liabilities
(i) Borrowings 33.40 26.10 18.75 7.95 11.72
(ii) Lease liabilities 10.57 4.84 2.90
(iii) Other financial liabilities 8.86 8.11 8.08 8.48 8.91
Provisions 11.30 13.31 15.67 17.05 18.98
Deferred tax liabilities (Net) 2.03 1.10 0.46 0.24
Other non-current liabilities 0.58 0.5788 0.5075 0.5075 0.5075
Non current tax liabilities (Net) 1.74 1.5282 1.9054
Total non-current liabilities 57.91 50.74 55.96 38.82 43.26
Current liabilities
Financial liabilities
(i) Borrowings 112.54 66.73 85.82 43.43 36.36
(ii) Lease liabilities 9.75 6.10 4.24
(iii) Trade payables
(a) Total outstanding dues of micro and
small enterprises 1.47 6.17 9.15 15.05 30.36
(b) Total outstanding dues of creditors
other than micro and small enterprises 362.42 408.93 470.84 520.27 493.13
(iv) Other financial liabilities 41.88 42.81 43.79 31.06 32.39
Other current liabilities 269.58 307.79 318.98 251.84 308.49
Provisions 4.53 4.48 5.69 5.25 7.34
Current tax liabilities (net) 11.95 15.39 17.13 25.76 15.01
Total current liabilities 804.37 852.29 961.15 898.77 927.31
Total Liabilities 862.28 903.03 1,017.11 937.59 970.58
Total equity and liabilities 1,065.22 1,165.25 1,382.19 1,443.31 1,625.41

• CASH FLOW STATEMENT
Cash Flow Statement FY18 FY19 FY20 FY21 FY22

Cash flow from operating activities
Profit before tax 66.32 101.27 130.30 195.11 216.91
Adjustments 12.81 24.78 19.08 27.79 21.60
Operating cash flow before working capital
79.13 126.05 149.38 222.90 238.52
changes
Net working capital changes 35.57 34.44 -14.99 24.05 -75.77
Cash generated from operations 114.71 160.49 134.40 246.95 162.75
Income-taxes paid -28.58 -33.87 -36.48 -49.90 -71.37
Net cash provided by operating activities (A) 86.13 126.61 97.92 197.05 91.38
Cash flow from investing activities
Purchase of property, plant and equipment -29.22 -30.69 -32.05 -29.95 -50.02
Proceeds from sale of property, plant and
0.12 0.20 0.36 0.02 0.26
equipment
Investments made in others -0.25 -0.01 -3.66
Bank deposit made during the year (with
-157.38 -89.37 -141.43 -76.36 -91.73
maturity more than three months)
Bank deposit matured during the year (with
12.08 40.07 115.27 39.72 33.19
maturity more than three months)
Proceeds from sale of treasury shares 21.89
Dividend received 0.02 0.06 0.02 0.01 0.02
Interest received 8.40 9.34 18.01 37.33 19.94
Net cash used in investing activities (B) -166.22 -70.40 -17.94 -29.24 -92.00
Cash flow from financing activities
Repayment of borrowings -58.9168 -97.71 -28.22 -55.3077 -18.7892
Proceeds from borrowings 112.85 42.58 43.48 7.16 20.03
Payment of lease liability -12.60 -11.94 -8.18
Equity contribution by minority 0.39 0.57
Dividend paid -4.79 -4.85 -11.62 -2.94 -12.14
Dividend tax paid -0.86 -0.90 -2.30
Finance cost -17.1417 -18.087 -13.415 -11.6827 -8.3515
Net cash (used in) / generated from financing
31.14 -78.97 -24.30 -74.70 -26.86
activities (C)
Net cash flow during the year (A+B+C) -48.95 -22.75 55.68 93.11 -27.48
Cash and cash equivalents at the beginning of
117.10 67.25 45.17 101.46 197.23
the year
Addition on acquisition of subsidiary 0.09

Cash and cash equivalents of Astha Technical
Services Ltd. on amalgamation with Total 0.03
Water Management Services (India) Ltd.
Effect of FX -0.93 0.59 0.61 2.66 -0.67
Cash and cash equivalents at the end of the
67.25 45.17 101.46 197.23 169.08
year
FCF 56.79 95.73 65.51 167.09 41.10
• RATIO ANALYSIS
Margins FY18 FY19 FY20 FY21 FY22
GPM 35.4% 37.4% 34.8% 38.5% 40.0%
EBITDAM 7.7% 9.4% 9.3% 14.1% 13.6%
EBITM 6.4% 7.7% 7.7% 12.2% 11.9%
NPM 3.8% 5.6% 6.3% 9.9% 10.2%
Return Ratios FY18 FY19 FY20 FY21 FY22
DUPONT ROE
NPM 3.8% 5.6% 6.3% 9.9% 10.2%
Total asset turnover 1.03 1.04 1.16 1.03 1.03
Leverage factor 5.45 4.80 4.06 3.24 2.64
ROE 21.4% 28.1% 29.9% 32.9% 27.8%
ROCE 27.6% 31.1% 31.2% 36.6% 30.1%
ROIC 14.2% 19.0% 26.1% 46.4% 49.1%
Debt Ratios FY18 FY19 FY20 FY21 FY22
Debt/Equity 0.72 0.35 0.34 0.12 0.08
Interest Coverage 3.08 4.18 5.94 12.01 14.77

Efficiency Ratios FY18 FY19 FY20 FY21 FY22
Receivable days 149 135 114 120 111
Inventory Days 62 58 50 54 60
Payable days 213 188 168 209 193
Cash Conversion Days -2 5 -4 -36 -23
Purchases 648 756 970 885 999
Cash flow Conversion Ratios FY18 FY19 FY20 FY21 FY22
CFO/PAT 216% 194% 104% 137% 57%
CFO/EBITDA 143.3% 147.4% 97.5% 120.8% 75.7%
FCF yield 5.4% 8.2% 4.4% 11.5% 2.6%
Asset Turnover Ratios FY18 FY19 FY20 FY21 FY22
Total Asset Turnover 1.03 1.04 1.16 1.03 1.03
Net Fixed Asset Turnover 8.67 7.90 8.85 7.94 8.75

FINANCIAL SHENANIGANS
Financial Shenaningans FY18 FY19 FY20 FY21 FY22 CAGR Remark

Sales 1045.81 1162.28 1479.83 1449.52 1576.87 10.81%
Grown slower
Accounts Receivables 437.10 424.17 501.87 448.96 507.70 3.81% than sales
AR % of Sales 41.80% 36.49% 33.91% 30.97% 32.20%
Higher
inventory in
WIP is ordinary
course of
Inventory 101.19 129.76 134.50 127.59 180.96 15.64% business
Contingent Liabilities 43.90 50.51 52.84 64.29 58.06

Equity 200.11 260.03 363.05 505.84 655.66
Reduced
21.94% 19.42% 14.55% 12.71% 8.86% overtime
Director's Remuneration 3.71 4.84 5.42 5.77 6.63

NP 39.96 65.34 93.71 143.40 161.27
Reduced
9.28% 7.41% 5.78% 4.02% 4.11% overtime
Auditor fees 0.41 0.47 0.52 0.50 0.57 8.46% Negligible

Auditor fees as % Sales 0.039% 0.040% 0.035% 0.035% 0.036%
Operating Expenses 110.73 126.84 139.48 123.39 141.81
Auditor fees as % Operating
Expenses 0.372% 0.368% 0.372% 0.408% 0.402%

• RELATED PARTY TRANSACTION
RPT during the year FY18 FY19 FY20 FY21 FY22

Sale of goods 76.54 112.71 125.76 143.54 154.21
Services rendered 0.79 0.80 0.77 0.21 0.90
Rental income 0.78 0.84 0.92 0.94 0.99
Interest income on loan and 12.36 11.80 11.42 9.23 9.67
advances
Management fees 0.66 0.77 0.89 0.87 0.84
Purchase of goods 4.51 16.13 11.82 6.11 5.65
Services received 29.77 33.67 31.99 39.05 32.87
Purchase of miscellaneous 0.71 0.74 0.74 0.00 0.00
items
Rental expenses 0.40 0.40
Interest paid on inter 0.09 0.08 0.21 0.34 0.33
corporate deposits
Provision for doubtful debts 4.68 9.53
Loans and advances given 58.49 60.21 61.51 54.82 28.68
Loans and advances repaid 57.87 64.95 66.23 46.91 23.54
Inter corporate deposits 1.13 2.08 0.29 0.65
received
Inter corporate deposits 0.25 0.82 0.00 0.00
repaid
Dividend received 0.86 0.96 1.301 1.26 0.30
Dividend paid 1.14 1.14 3.09 0.60 4.00
Remuneration 7.05 7.61 8.23 8.02 9.64
Commission to executive 1.50 2.00 3.00 3.00
directors
Directors Sitting Fees 0.33 0.28 0.34 0.32 0.29
Directors commission 0.70 0.98 1.30 1.75 1.75
CSR expenses 0.99 1.24 1.60 1.62 2.80
Investments made during 2.50 0.58 0.00 1.05
the year
Corporate guarantees 0.86 0.77 0.71 0.61 0.45
commission
Corporate guarantees 3.39 0.00 4.18
issued
discharged
Contribution to post- 4.04 4.84 5.23 4.00 5.71
employment
benefit plans
Total 265.25 338.26 346.71 346.63 313.35

Outstanding FY18 FY19 FY20 FY21 FY22
Inter corporate deposits 0.82 1.13 3.21 3.50 4.15
(Outstanding)
Outstanding loans and 83.49 79.72 67.85 76.44 82.98
advances
Advance to suppliers 8.83 6.25 7.24 8.03 8.93
Advance from customer 0.87 0.24
Outstanding receivables (Net of payables) excluding 78.78 76.10 77.47 85.40 89.90
loans and advances
Outstanding payables (Net of receivables) excluding 0.04 0.10 0.06 0.36 0.03
loans and
advances
Investment in equity shares / 56.89 60.10 61.38 61.99 63.48
debentures
(Outstanding)

VALUATIONS
Income Statement FY18 FY19 FY20 FY21 FY22 FY23E FY24E

Revenue 1045.81 1162.28 1479.83 1449.52 1576.87 2049.93 2295.92
11.1% 27.3% -2.0% 8.8% 30.0% 12.0%
COGS 675.59 727.52 965.33 891.9 945.74 1277.79 1429.63
Gross Profit 370.22 434.76 514.50 557.62 631.13 772.14 866.30
GPM 35.4% 37.4% 34.8% 38.5% 40.0% 37.7% 37.7%
Operating
Manufacturing
Expenses 179.44 199.04 237.17 229.82 274.20 320.20 365.34
Operating Expenses 110.73 126.84 139.48 123.39 141.81 164.95 156.57
EBITDA 80.05 108.88 137.85 204.41 215.12 286.99 344.39
EBITDAM 7.7% 9.4% 9.3% 14.1% 13.6% 14.0% 15.0%
DA 13.08 19.59 23.53 27.67 28.04 23.24 34.04

EBIT 66.97 89.29 114.32 176.74 187.08 263.75 310.35
EBITM 6.4% 7.7% 7.7% 12.2% 11.9% 12.9% 13.5%
Other Income 21.09 33.34 35.37 33.09 42.5 30 30

Interest 21.74 21.35 19.25 14.72 12.67 10.5 8
EBT 66.32 101.28 130.44 195.11 216.91 283.25 332.35
EBTM 6.3% 8.7% 8.8% 13.5% 13.8% 13.8% 14.5%
Taxes 26.36 35.94 36.73 51.71 55.64 79.31 93.06

39.7% 35.5% 28.2% 26.5% 25.7% 28.0% 28.0%
PAT 39.96 65.34 93.71 143.40 161.27 203.94 239.29

NPM 3.8% 5.6% 6.3% 9.9% 10.2% 9.9% 10.4%
(03-11-2022) FY22 FY24E

M-cap 3031
CMP 2067
FY24 Target P/E 16.00
Target M-cap 3828.68
Target Price 2610.98
Upside Potential 26.32%

Historical PE
30
25
20
15
10
0
01-Apr-2019 01-Apr-2020 01-Apr-2021 01-Apr-2022
Median SD+1 SD-1 Cons TTM PE(x)
• Going forward, we estimate a 21% CAGR till FY24, driven by revenue recognition in major EPC
projects, growth from the Chemical division and Consumable product division. We expect IEIL to
post a PAT CAGR of ~22% during FY22-24E driven by EPC efficiencies and Chemical division margin
improvement. Currently, IEIL is trading at a 18.2x PE multiple, we assign a FY24E PE multiple of 16x.
We arrive at a target price of Rs. 2,610, which represents an upside of 26% from CMP which we
believe can be achieved within 12 months.

BIBLIOGRAPHY
• CMIE
• ACE Equity
• KamayaKya research
• CONCORD ENVIRO SYSTEMS LIMITED RHP
• IEIL Annual reports since listing
• IEIL Investor presentations since listing
• IEIL Earning conference call transcripts since listing
• IEIL website
• IEIL – Notifications to BSE
• Public information of companies in Waste water and treatment industries
• Management interviews.

DISCLOSURES:
About the Company and the Business Activity:
Kamayakya Wealth Management Private Limited (CIN: U74999PN2021PTC205529) (“the Company”) is

incorporated on October 23, 2021 in Pune, Maharashtra.
The Company is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 vide SEBI
Reg. No. INH000009843 and engaged in the business of providing research analyst services, as well as in
other research activities including activities engaged in preparation and/or publication of research report
or research analysis or making “buy/sell/hold” recommendation on securities including options and
derivatives or giving price target or offering an opinion concerning public offer by companies and
The company does not provide investment banking or merchant banking or brokerage services.
Disciplinary History:
There has been no instance of any disciplinary action, penalty etc. levied/passed by any
regulation/administrative agencies against the Company and its Directors.
SEBI has not issued any administrative warning to the Company.

Terms & Conditions of issuance of Research Report:
The Research report is issued to the registered clients who have subscribed to the services.
The Research Report is based on the facts, figures and information that are considered true, correct, and
reliable. The information is obtained from publicly available media or other sources believed to be reliable.
The report is prepared solely for informational purpose and does not constitute an offer document or
solicitation to buy or sell or subscribe for securities or other financial instruments for clients.
Details of associates:
• Currently there are no associates.

Disclosures as Regulation 19 of the SEBI (Research Analyst) Regulations, 2014
Sr.No. Disclosure Yes/No

A Disclosures with regard to ownership and material conflicts of interest:
1 The Company or its research analysts, or his/her relative or associate has any direct or NO
indirect financial interest in the subject The Company.
2 The Company or its research analysts, or his/her relative or associate has any other NO
material conflict of interest at time of publication of the research report.
3 The Company or its research analysts, or his/her relative or associates have actual NO
ownership of 1% (one percent) or more securities of the subject The Company.
B Disclosures with regard to receipt of compensation:
1 The Company or its associates have received any compensation from the subject The NO
Company in the past twelve months.
2 The Company or its associates have managed or co-managed public offering of NO
securities for the subject in the past twelve months.
3 The Company or its associates have received any compensation or other benefits from NO
the subject The Company or third party in connection with the research report
C Other Disclosures:
1 The research analyst has served as an officer, director, employee of the subject The NO
Company
2 The Company or its research analyst has been engaged in market making activity for NO
the subject The Company.
Subject company means the company on which the recommendation is given and the research report is
issued.
Definitions of Terms Used:
TERM DEFINITION
BUY Expected absolute returns of more than 20% over a specified time period.
Expected absolute returns between 20% and -15% over a specified time
HOLD period.
SELL Expected absolute returns of less than -15% over a specified time period.
ENTRY PRICE Price at which the stock was recommended.
TARGET PRICE Expected price of the stock at the end of a specified time period.
POTENTIAL
UPSIDE Expected absolute returns from entry price over a specific time period.
UPSIDE LEFT Expected absolute returns from current market price to target price.

Disclaimers:
This Research Report (hereinafter called report) has been prepared and presented by Kamayakya Wealth
Management Private Limited, which does not constitute any offer or advice to sell or does solicitation to
buy any securities. The information presented in this report, are for the intended recipients only. Further,
the intended recipients are advised to exercise restraint in placing any dependence on this report, as the
sender, Kamayakya Wealth Management Private Limited, neither guarantees the accuracy of any
information contained herein nor assumes any responsibility in relation to losses arising from the errors
of fact, opinion or the dependence placed on the same.
Despite the information in this document has been previewed on the basis of publicly available
information, internal data, personal views of the research analyst(s)and other reliable sources, believed to
be true, we do not represent it as accurate, complete or exhaustive.
It should not be relied on as such, as this document is for general guidance only. Besides this, the research
analyst(s) are bound by stringent internal regulations and legal and statutory requirements of the
Securities and Exchange Board of India (SEBI) and the analysts' compensation was, is, or will be not directly
or indirectly related with the other companies and/or entities of and have no bearing whatsoever on any
recommendation, that they have given in the research report. Kamayakya Wealth Management Private
Limited or any of its affiliates/group companies shall not be in any way responsible for any such loss or
damage that may arise to any person from any inadvertent error in the information contained in this
report. Kamayakya Wealth Management Private Limited has not independently verified all the information,
which has been obtained by the company for analysis purpose, from publicly available media or other
sources believed to be reliable. Accordingly, we neither testify nor make any representation or warranty,
express or implied, of the accuracy, contents or data contained within this document. Affiliates of
Kamayakya Wealth Management Private Limited are engaged in investment advisory services.
We hereby declare that the information herein may change any time due to the volatile market conditions,
therefore, it is advised to use own discretion and judgment while entering into any transactions,
whatsoever. Individuals employed as research analyst by Kamayakya Wealth Management Private Limited
or their associates are not allowed to deal or trade in securities, within thirty days before and five days
after the publication of a research report as prescribed under SEBI Research Analyst Regulations. Subject
to the restrictions mentioned in above paragraph, we and our affiliates, officers, directors, employees, and
their relative may: (a) from time to time, have long or short positions acting as a principal in, and buy or
sell the securities or derivatives thereof, of Company mentioned herein or (b) be engaged in any other
transaction involving such securities and earn profits.
Compliance Officer:
Aniket Kulkarni
E-mail Address: [email protected]
Phone Number: +91-9175939641

[email protected]
www.kamayakya.com

Ion Exchange (India) Ltd. (IEIL) - Detailed Report

Uploaded by

Copyright:

Available Formats

Ion Exchange (India) Ltd. (IEIL) - Detailed Report

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ion Exchange (India) Ltd. (IEIL) - Detailed Report

Uploaded by

Copyright:

Available Formats

SEBI Research Analyst Registration No: INH000009843

CMP: 2066.7| Target Price: 2610

Market Capitalisation : ₹732 Cr

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

1. He has an experience of more than 4 decades in providing Total Water

2. He established the company’s international business division, including

3. Mr. Sharma has chaired technical seminar sessions organized by

4. He holds 5.62% of total equity share and takes total remuneration of

● AANKUR PATNI, EXECUTIVE DIRECTOR

2. He is currently associated with 8 Companies and is a director with

3. He holds 2.01 % of Total equity shares and takes total remuneration of

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

GLOBAL WATER AND WASTEWATER TREATMENT SOLUTIONS MARKET

Global Water and Wastewater Treatment Solutions Market Size: Historical

Water and Wastewater Treatment Solutions Market Forecast

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

INDIA’S WATER AND WASTEWATER TREATMENT SOLUTIONS MARKET

India’s Water and Wastewater Treatment Solutions Market

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

Total Water and Wastewater Treatment Solutions Market Forecast

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

Industrial Wastewater Treatment Solutions Market Forecast

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

Sewage Generation and Treatment Capacity, Urban India, 2020,

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

Source- Concord Enviro Systems Limited RHP

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

• The Company has in-house manufacturing of membranes which is used in different

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

Engineering Chemical Consumer products

1. ENGINEERING (58% OF FY22 SALES, 10-12% EBIT MARGIN)

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

i. Packaged and pre-engineered range – The Company provides solutions for

b) COMPREHENSIVE SERVICES- O&M CONTRACTS

Sea Water RO Membrane Low Pressure RO Membranes Brackish Resistant Membranes

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

c) Industrial, institutional and domestic applications of membranes are as follows:

i. Conventional Industrial Water Treatment – Brackish water Hydramem

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

a) Study input raw water quality.

3. CONSUMER PRODUCTS (8% OF FY22 SALES, NEGATIVE EBIT MARGIN IN FY22)

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

Location Type of unit

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

● Exports contributes 30% to the total revenues.

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

ONGOING UP PROJECT AND UPCOMING EPC PROJECTS TO START CONTRIBUTING TO THE

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

HUGE GROWTH IN CONSUMER DIVISION ALONGWITH PROFITABILITY

STRONG REVENUE VISIBLITY WITH MARGIN IMPROVEMENT IN CHEMICAL BUSINESS

SEBI Research Analyst Registration No : INH000009843 www.kamayakya.com

CONSOLIDATION OF ALL SUBSIDIARIES TO REDUCE RELATED PARTY TRANSACTIONS

TAILWINDS TO THE WATER AND WASTE WATER TREATMENT INDUSTRY